BioSpace News Archive

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced its participation in the Piper Sandler 32nd Annual Healthcare Conference to be held virtually December 1 – 3, 2020.

Researchers at Massachusetts General Hospital and University of Pennsylvania will examine the effects of COVID-19 on the placenta and immune system

Affordable systems and services provider enhances platform connectivity by adding creator of custom medical practice and healthcare IT solutions

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol ® Cyclo™) in the treatment of Niemann-Pick Disease Type C (NPC) today announced that the compa

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors

– Proceeds to support advancing therapies for the treatment of myeloproliferative diseases through further clinical investigation – Financing round led by Farallon Capital Management, LLC

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) combined with targeted therapies for the treatment of cancer, today announced the promotion of Tirtha Chakraborty, PhD, to Chief Scientific Officer. Dr. Chakraborty brings significant expertise in hematology and genetic engineering to the company’s top science position. “This year has been one of significant progress for Vor

XBiotech Inc. (NASDAQ: XBIT) announced today new data for its breakthrough candidate therapy for treating infections of influenza and COVID-19.

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with CBPO Holdings Limited (“Parent”) and CBPO Group Limited (“Merger Sub”

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Robin A. Walker, J.D, as Chief Legal Officer, effective immediately